Conference Proceedings

Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER breast cancer with KAT6A dysregulation

Shikhar Sharma, Jay Chung, Sean Uryu, Amanda Rickard, Natalie Nady, Showkhin Khan, Zhenxiong Wang, Yong Zhang, Haikuo Zhang, Pei-Pei Kung, Eric Greenwald, Karen Maegley, Patrick Bingham, Hieu Lam, Ylva E Bozikis, Hendrik Falk, Elizabeth Allan, Vicky M Avery, Miriam S Butler, Michelle A Camerino Show all

Experimental and Molecular Therapeutics | American Association for Cancer Research | Published : 2021